Zevra Therapeutics Inc
NASDAQ:ZVRA
Balance Sheet
Balance Sheet Decomposition
Zevra Therapeutics Inc
Zevra Therapeutics Inc
Balance Sheet
Zevra Therapeutics Inc
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
3
|
2
|
10
|
32
|
17
|
11
|
18
|
3
|
4
|
112
|
66
|
43
|
34
|
62
|
|
| Cash Equivalents |
3
|
2
|
10
|
32
|
17
|
11
|
18
|
3
|
4
|
112
|
66
|
43
|
34
|
62
|
|
| Short-Term Investments |
0
|
0
|
0
|
19
|
51
|
31
|
3
|
0
|
0
|
0
|
17
|
25
|
36
|
129
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
5
|
2
|
0
|
2
|
3
|
2
|
8
|
17
|
11
|
23
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
5
|
2
|
0
|
2
|
2
|
1
|
7
|
16
|
10
|
23
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
| Other Current Assets |
0
|
0
|
0
|
3
|
2
|
3
|
2
|
2
|
2
|
1
|
2
|
2
|
4
|
7
|
|
| Total Current Assets |
3
|
2
|
10
|
54
|
74
|
47
|
24
|
7
|
8
|
115
|
93
|
87
|
86
|
223
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
3
|
2
|
2
|
2
|
2
|
1
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
2
|
0
|
2
|
3
|
2
|
2
|
2
|
2
|
1
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
2
|
2
|
1
|
2
|
2
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
69
|
69
|
6
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
5
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
8
|
3
|
0
|
0
|
0
|
15
|
20
|
0
|
6
|
48
|
|
| Other Long-Term Assets |
0
|
0
|
3
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
10
|
11
|
1
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
5
|
|
| Total Assets |
3
N/A
|
2
-17%
|
14
+471%
|
55
+299%
|
85
+55%
|
53
-38%
|
27
-49%
|
11
-61%
|
11
+7%
|
133
+1 087%
|
116
-13%
|
172
+49%
|
178
+3%
|
285
+60%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
2
|
5
|
1
|
8
|
4
|
5
|
1
|
1
|
4
|
14
|
39
|
2
|
|
| Accrued Liabilities |
1
|
1
|
2
|
0
|
6
|
0
|
5
|
0
|
6
|
3
|
3
|
15
|
13
|
10
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
4
|
0
|
3
|
0
|
4
|
4
|
0
|
1
|
0
|
5
|
38
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
7
|
8
|
27
|
|
| Total Current Liabilities |
1
|
5
|
4
|
8
|
7
|
12
|
12
|
5
|
8
|
4
|
12
|
74
|
34
|
39
|
|
| Long-Term Debt |
0
|
0
|
18
|
19
|
91
|
90
|
79
|
78
|
68
|
0
|
13
|
5
|
60
|
62
|
|
| Other Liabilities |
2
|
3
|
16
|
38
|
6
|
9
|
3
|
2
|
2
|
2
|
5
|
32
|
45
|
29
|
|
| Total Liabilities |
4
N/A
|
8
+125%
|
38
+369%
|
65
+70%
|
104
+60%
|
110
+6%
|
93
-15%
|
85
-9%
|
78
-9%
|
6
-93%
|
30
+412%
|
110
+272%
|
138
+25%
|
130
-6%
|
|
| Equity | |||||||||||||||
| Common Stock |
20
|
20
|
24
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
21
|
26
|
50
|
105
|
121
|
165
|
221
|
246
|
259
|
267
|
309
|
400
|
505
|
422
|
|
| Additional Paid In Capital |
0
|
0
|
2
|
95
|
103
|
107
|
155
|
171
|
192
|
397
|
402
|
473
|
555
|
588
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
8
|
11
|
11
|
11
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Equity |
1
N/A
|
6
-850%
|
24
-326%
|
10
+58%
|
19
-85%
|
58
-207%
|
67
-16%
|
75
-12%
|
66
+11%
|
127
N/A
|
86
-32%
|
62
-28%
|
40
-36%
|
155
+290%
|
|
| Total Liabilities & Equity |
3
N/A
|
2
-17%
|
14
+471%
|
55
+299%
|
85
+55%
|
53
-38%
|
27
-49%
|
11
-61%
|
11
+7%
|
133
+1 087%
|
116
-13%
|
172
+49%
|
178
+3%
|
285
+60%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
5
|
35
|
35
|
42
|
54
|
57
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|